Overview

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER fixed doses versus placebo in the treatment of outpatients with major depressive disorder.
Phase:
Phase 3
Details
Lead Sponsor:
Forest Laboratories
Treatments:
Levomilnacipran
Milnacipran